Vita Life Sciences
Pharmaceuticals, Biotechnology & Life Sciences
Short position
Vita Life Sciences (ASX:VLS) has 0.00% of its shares on issue reported as short positions as of 21 Sept 2026, or about 114 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. VLS is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Vita Life Sciences (VLS) financials
Results, ratios and statements
Latest result
12 months to 30 Jun 2026 (TTM Jun 26) vs TTM Jun 25, figures in AUD, the reporting currency
- Revenue
- $96.0Mvs n/a (TTM Jun 25)
- Yahoo Finance, as at 29 Sep 2026
- NPAT
- $11.2Mvs n/a (TTM Jun 25)
- Yahoo Finance, as at 29 Sep 2026
- EPS (diluted)
- $0.20vs $0.17 (TTM Jun 25)
- Yahoo Finance, as at 29 Sep 2026
- Rev YoY
- +17.3%FY
- EPS YoY
- +19.4%TTM
Key ratios
12 months to 30 Jun 2026 (TTM); balance sheet at 31 Dec 2025, 6 months before; prices to 9 Oct 2026
- Gross margin
- 62.8%
- Operating margin
- 15.8%
- Net margin
- 11.6%
- FCF margin
- 15.2%
- ROE
- 20.5%
- ROA
- 14.5%
- FCF conversion
- 1.31×
- Net cash (excl. leases)
- $35.6M
- Net debt / EBITDA
- −2.2×
- Current ratio
- 2.7×
- Interest cover
- 59.9×
- Cash dividends paid / net profit
- 68.6%
- Market cap
- $154.3M
- P/E
- 14.1×
- P/B
- 2.7×
Ratios use the reporting currency (AUD); market cap is in AUD. Source: Yahoo Finance, as at 29 Sep 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | TTM Jun 26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| Revenue | $96.0M | $93.3M | $79.5M | $74.2M | $66.9M |
| Gross profit | $60.3M | $57.0M | $47.2M | $43.1M | $39.7M |
| Operating income | $15.2M | $14.1M | $11.7M | $11.9M | $10.7M |
| EBITDA | $16.0M | $15.8M | $13.5M | $13.1M | $11.4M |
| EBIT | $16.0M | $14.8M | $12.8M | $12.6M | $10.8M |
| Interest expense | $254.0K | $353.0K | $209.0K | $135.0K | $34.0K |
| Pretax income | $15.7M | $14.4M | $12.6M | $12.5M | $10.7M |
| Tax | $4.6M | $4.0M | $3.9M | $3.4M | $3.4M |
| NPAT | $11.2M | $10.4M | $8.8M | $9.1M | $7.1M |
| Net interest income | $782.0K | $638.0K | $830.0K | $423.0K | $97.0K |
| EPS basic | $0.20 | $0.19 | $0.16 | $0.17 | $0.13 |
| EPS diluted | $0.20 | $0.18 | $0.16 | $0.17 | $0.13 |
| Shares | n/a | 55.5M | 56.6M | 56.4M | 53.0M |
Financial reports
The company's own filings, newest first
- Half Year PresentationHalf Year Results18 Aug 2026via asx_announcements
- Half Yearly Report and AccountsHalf Year Results17 Aug 2026via asx_announcements
- Annual Report to shareholdersAnnual Report26 Mar 2026via asx_announcements
- Preliminary Final ReportAnnual Results16 Feb 2026via asx_announcements
- Half Year PresentationHalf Year Results25 Aug 2025via asx_announcements
- Half Year AccountsHalf Year Results25 Aug 2025via asx_announcements
- Annual Report to shareholdersAnnual Report24 Mar 2025via asx_announcements
- Preliminary Final ReportAnnual Results24 Feb 2025via asx_announcements
- Half Year PresentationHalf Year Results26 Aug 2024via asx_announcements
- Half Year AccountsHalf Year Results26 Aug 2024via asx_announcements
Showing 10 of 59 reports